Company news

Evaxion A/S news in 2026

Evaxion A/S's news releases, calls and decks from 2026, newest first.

View company

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

November 4, 2026

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

November 3, 2026

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

October 30, 2026

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 23, 2026

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

October 19, 2026

Decks in 2026